Stay updated with the latest from ClexBio.
ClexBio was selected to compete with 4 finalists and wins the 2022 DNB Healthcare Prize. The prize comes with a USD 100k check, which will continue to propel our pre-clinical program, and a showcase on the NASDAQ billboard on Times Square - auspice of bigger things to come.Learn More
EQT Foundation, part of EQT Group, publishes feature on ClexBio highlighting its innovative technology platform and the unique potential it has to revolutionize human tissue transplantation. EQT Group is one of the premier private equity and venture investment groups in the world and is one of Europe’s largest and most experienced healthcare investors.Learn More
ClexBio appoints Andreas Lehmann and Wasim Q. Malik to its Board of Directors, further bolstering depth of commercial industry experience in its leadership and broadening its footprint in the US.Learn More
ClexBio and CSEM, a world-leading public-private technology innovator in Switzerland, have teamed up to develop the world’s first machine capable of growing tissue-engineered human veins in the lab.Learn More
ClexBio, a start-up developing bioengineered human blood vessels for transplant, has secured US$2.2m in seed funding from private investors and governmental grants to develop bio-engineered human blood vessel transplantsLearn More
Sphere Fluidics and ClexBio announce the launch of the CYTRIX Microfluidic Hydrogel Kit. The kit combines ClexBio’s novel CYTRIX Hydrogel with Sphere Fluidics’ Pico-Gen™ double aqueous biochip to allow the plug-and-play generation of reproducible and tailorable hydrogel microstructures for 3D cell culture, organoids, single-cell analysis, and many other applications.Learn More